Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RCKT | US
-0.55
-3.24%
Healthcare
Biotechnology
30/06/2024
04/10/2024
16.41
16.06
16.52
16.03
Rocket Pharmaceuticals Inc. together with its subsidiaries operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas Medioambientales y Tecnológicas Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company is headquartered in Cranbury New Jersey.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
62.3%1 month
77.2%3 months
61.3%6 months
55.4%-
-
4.37
0.07
0.06
-7.77
-
-
-261.48M
1.49B
1.49B
-
-
-
-
-64.31
17.54
26.28
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
5.26
Range1M
5.98
Range3M
10.95
Rel. volume
1.16
Price X volume
20.92M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Ardelyx Inc | ARDX | Biotechnology | 6.82 | 1.61B | -1.59% | n/a | 71.36% |
Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 18.82 | 1.60B | -3.19% | n/a | 0.26% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Belite Bio Inc | BLTE | Biotechnology | 50.99 | 1.56B | 4.68% | n/a | 0.00% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 9.84 | 1.53B | 5.69% | n/a | 19.83% |
Arcus Biosciences Inc | RCUS | Biotechnology | 16.65 | 1.52B | 8.19% | n/a | 1.73% |
IRON | IRON | Biotechnology | 49.93 | 1.48B | -2.48% | n/a | 0.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -7.77 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 4.37 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 61.29 | 74.67 | Par |
Debt to Equity | 0.07 | -1.82 | Expensive |
Debt to Assets | 0.06 | 0.26 | Cheaper |
Market Cap | 1.49B | 3.73B | Emerging |